Center for Substance Abuse Research, Lewis Katz School of Medicine, Temple University. Philadelphia, Pennsylvania
Center for Substance Abuse Research, Lewis Katz School of Medicine, Temple University. Philadelphia, Pennsylvania.
Pharmacol Rev. 2023 Nov;75(6):1062-1118. doi: 10.1124/pharmrev.121.000506. Epub 2023 Jun 15.
Oxycodone, a semisynthetic derivative of naturally occurring thebaine, an opioid alkaloid, has been available for more than 100 years. Although thebaine cannot be used therapeutically due to the occurrence of convulsions at higher doses, it has been converted to a number of other widely used compounds that include naloxone, naltrexone, buprenorphine, and oxycodone. Despite the early identification of oxycodone, it was not until the 1990s that clinical studies began to explore its analgesic efficacy. These studies were followed by the pursuit of several preclinical studies to examine the analgesic effects and abuse liability of oxycodone in laboratory animals and the subjective effects in human volunteers. For a number of years oxycodone was at the forefront of the opioid crisis, playing a significant role in contributing to opioid misuse and abuse, with suggestions that it led to transitioning to other opioids. Several concerns were expressed as early as the 1940s that oxycodone had significant abuse potential similar to heroin and morphine. Both animal and human abuse liability studies have confirmed, and in some cases amplified, these early warnings. Despite sharing a similar structure with morphine and pharmacological actions also mediated by the -opioid receptor, there are several differences in the pharmacology and neurobiology of oxycodone. The data that have emerged from the many efforts to analyze the pharmacological and molecular mechanism of oxycodone have generated considerable insight into its many actions, reviewed here, which, in turn, have provided new information on opioid receptor pharmacology. SIGNIFICANCE STATEMENT: Oxycodone, a -opioid receptor agonist, was synthesized in 1916 and introduced into clinical use in Germany in 1917. It has been studied extensively as a therapeutic analgesic for acute and chronic neuropathic pain as an alternative to morphine. Oxycodone emerged as a drug with widespread abuse. This article brings together an integrated, detailed review of the pharmacology of oxycodone, preclinical and clinical studies of pain and abuse, and recent advances to identify potential opioid analgesics without abuse liability.
羟考酮,一种半合成的天然蒂巴因(一种阿片生物碱)衍生物,已经有 100 多年的历史了。虽然蒂巴因由于高剂量会引起惊厥而不能用于治疗,但它已转化为许多其他广泛使用的化合物,包括纳洛酮、纳曲酮、丁丙诺啡和羟考酮。尽管早在早期就发现了羟考酮,但直到 20 世纪 90 年代才开始进行临床研究以探索其镇痛疗效。这些研究之后,又进行了多项临床前研究,以检查羟考酮在实验室动物中的镇痛效果和滥用倾向以及在人类志愿者中的主观效果。多年来,羟考酮一直处于阿片类药物危机的前沿,在阿片类药物滥用和滥用中发挥了重要作用,有迹象表明它导致了其他阿片类药物的滥用。早在 20 世纪 40 年代,就有人担心羟考酮具有与海洛因和吗啡相似的显著滥用潜力。动物和人类滥用倾向研究都证实了这一点,在某些情况下甚至放大了这些早期警告。尽管羟考酮与吗啡具有相似的结构,并且药理学作用也受 -阿片受体介导,但羟考酮在药理学和神经生物学方面存在一些差异。从许多分析羟考酮药理学和分子机制的努力中涌现的数据,为其许多作用提供了深入的了解,本文对此进行了综述,这反过来又为阿片受体药理学提供了新的信息。意义声明:羟考酮, -阿片受体激动剂,于 1916 年合成,并于 1917 年在德国引入临床使用。它作为一种治疗急性和慢性神经性疼痛的治疗性镇痛药进行了广泛研究,作为吗啡的替代品。羟考酮已成为一种广泛滥用的药物。本文汇集了关于羟考酮药理学、疼痛和滥用的临床前和临床研究以及最近的进展的综合、详细的综述,旨在确定具有潜在滥用倾向的阿片类镇痛药。